Table 1.
Distribution of chemotherapy regimens
| Induction regimen | Number of patients, n = 816 |
|---|---|
| IMiD | 489 (59.9%) |
| Lenalidomide dexamethasone | 382 |
| Lenalidomide, cyclophosphamide, dexamethasone | 38 |
| Thalidomide, melphalan, prednisone | 21 |
| Lenalidomide, melphalan, prednisone | 20 |
| Thalidomide dexamethasone | 20 |
| Lenalidomide | 6 |
| Pomalidomide dexamethasone | 1 |
| Lenalidomide bendamustine | 1 |
| PI | 185 (22.6%) |
| Bortezomib, cyclophosphamide, dexamethasone | 110 |
| Bortezomib dexamethasone | 63 |
| Bortezomib, doxorubicin, dexamethasone | 4 |
| Bortezomib, melphalan, prednisone | 3 |
| Bortezomib | 2 |
| Ixazomib, cyclophosphamide, dexamethasone | 2 |
| Bortezomib, cyclophosphamide, prednisone | 1 |
| IMiD and PI | 80 (9.8%) |
| Bortezomib, lenalidomide, dexamethasone | 59 |
| Bortezomib, thalidomide, dexamethasone | 8 |
| Carfilzomib, thalidomide, cyclophosphamide, dexamethasone | 5 |
| VDT-PACE | 3 |
| Ixazomib, lenalidomide, dexamethasone | 3 |
| Bortezomib, lenalidomide, cyclophosphamide, dexamethasone | 1 |
| Carfilzomib, lenalidomide, cyclophosphamide, dexamethasone | 1 |
| No novel agent | 62 (7.6%) |
| Dexamethasone | 31 |
| Melphalan prednisone | 26 |
| Melphalan dexamethasone | 2 |
| Cyclophosphamide prednisone | 1 |
| Cyclophosphamide dexamethasone | 1 |
| Prednisone | 1 |
IMiD indicates immunomodulatory drug; PI, proteosome inhibitor; and VDT-PACE, bortezomib, dexamethasone, lenalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide